MA44254A - Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques - Google Patents

Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques

Info

Publication number
MA44254A
MA44254A MA044254A MA44254A MA44254A MA 44254 A MA44254 A MA 44254A MA 044254 A MA044254 A MA 044254A MA 44254 A MA44254 A MA 44254A MA 44254 A MA44254 A MA 44254A
Authority
MA
Morocco
Prior art keywords
treat cancer
immunological disorders
bcma antibodies
bcma
antibodies
Prior art date
Application number
MA044254A
Other languages
English (en)
Inventor
Michael Feldhaus
Maureen Ryan
Django Sussman
Lori Westendorf
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MA44254A publication Critical patent/MA44254A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
MA044254A 2016-02-17 2017-02-16 Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques MA44254A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662296594P 2016-02-17 2016-02-17
US201662396084P 2016-09-16 2016-09-16

Publications (1)

Publication Number Publication Date
MA44254A true MA44254A (fr) 2018-12-26

Family

ID=59562012

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044254A MA44254A (fr) 2016-02-17 2017-02-16 Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques

Country Status (14)

Country Link
US (6) US20190194338A1 (fr)
EP (1) EP3416687A4 (fr)
JP (4) JP7152309B2 (fr)
KR (1) KR102816905B1 (fr)
CN (2) CN116063503A (fr)
AU (2) AU2017219747B2 (fr)
BR (1) BR112018016697A2 (fr)
CA (1) CA3011900A1 (fr)
HK (1) HK1259075A1 (fr)
IL (2) IL311107A (fr)
MA (1) MA44254A (fr)
MX (2) MX2018009700A (fr)
SG (2) SG10202007836WA (fr)
WO (1) WO2017143069A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311107A (en) 2016-02-17 2024-04-01 Seagen Inc BCMA antibodies and their use for the treatment of cancer and immune disorders
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3790629A1 (fr) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Procédés et compositions pour le traitement du cancer
CA3100187A1 (fr) * 2018-06-26 2020-01-02 Abl Bio, Inc. Anticorps anti-bcma et utilisation associee
MX2021000532A (es) 2018-07-19 2021-04-12 Regeneron Pharma Receptores antigénicos quiméricos con especificidad para bcma y usos de estos.
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
WO2020088631A1 (fr) 2018-11-01 2020-05-07 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions et procédés pour l'ingénierie des lymphocytes t
SG11202106481SA (en) * 2018-12-19 2021-07-29 Seagen Inc Controlled fucosylation of antibodies
JP7554759B2 (ja) * 2019-02-26 2024-09-20 ソレント・セラピューティクス・インコーポレイテッド Ｂｃｍａに結合する抗原結合性タンパク質
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
AU2020267057A1 (en) 2019-04-30 2021-11-18 Crispr Therapeutics Ag Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
DK3967329T3 (da) 2019-05-07 2026-05-11 Gracell Bioscience Shanghai Co Ltd Genmanipuleret immuncelle, der er målrettet mod bcma, og anvendelse deraf
US20220218835A1 (en) * 2019-05-31 2022-07-14 Medimmune, Llc Combination therapy
BR112022001546A2 (pt) * 2019-07-30 2022-03-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Anticorpo anti-bcma, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
CN112409482B (zh) * 2019-08-20 2022-08-26 杭州尚健生物技术有限公司 Bcma抗体
EP4023673A4 (fr) * 2019-10-10 2023-03-15 Suzhou Qin Pharmaceuticals Co., Ltd. Anticorps monoclonal humanisé ciblant bcma et ayant une réactivité croisée singe/etre humain
WO2021136308A1 (fr) * 2020-01-03 2021-07-08 Biosion Inc. Anticorps se liant à bcma et leurs utilisations
CN113248611B (zh) * 2020-02-13 2026-02-06 上海泰槿生物技术有限公司 抗bcma抗体、其药物组合物及应用
AU2021244215A1 (en) 2020-03-26 2022-10-13 Seagen Inc. Methods of treating multiple myeloma
CN115279781B (zh) * 2020-03-26 2025-05-09 上海翰森生物医药科技有限公司 抗体药物偶联物及其医药用途
BR112022020332A2 (pt) 2020-04-10 2022-12-13 Seagen Inc Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
JP2023548538A (ja) 2020-11-08 2023-11-17 シージェン インコーポレイテッド 併用療法
CA3213636A1 (fr) 2021-03-18 2022-09-22 Seagen Inc. Liberation selective de medicament a partir de conjugues internalises de composes biologiquement actifs
MX2023012364A (es) 2021-04-20 2023-11-01 Seagen Inc Modulacion de citotoxicidad celular dependiente de anticuerpos.
IL308795A (en) 2021-05-28 2024-01-01 Seagen Inc Anthracycline antibody conjugates
CA3228311A1 (fr) 2021-08-12 2023-02-16 Ke HE Proteine recombinante bispecifique et son utilisation
WO2023019398A1 (fr) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Anticorps ciblant bcma, récepteurs antigéniques chimériques et leurs utilisations
TW202327650A (zh) 2021-09-23 2023-07-16 美商思進公司 治療多發性骨髓瘤之方法
US20250130233A1 (en) * 2021-10-27 2025-04-24 Janssen Biotech, Inc. Methods for enhanced bcma immunohistochemistry detection in human and monkey tissue
CN116333134A (zh) * 2021-12-22 2023-06-27 上海君实生物医药科技股份有限公司 抗bcma抗体及其用途
IL315508A (en) 2022-03-17 2024-11-01 Seagen Inc Camptothecin conjugates
WO2024129756A1 (fr) 2022-12-13 2024-06-20 Seagen Inc. Conjugués anticorps-médicament modifiés par la cystéine spécifiques d'un site
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN119548619A (zh) * 2023-08-10 2025-03-04 亘喜生物科技（上海）有限公司 一种双靶点car-t细胞在治疗系统性红斑狼疮及其他b细胞自身免疫病中的用途
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025090774A1 (fr) 2023-10-24 2025-05-01 Seagen Inc. Composés chimiothérapeutiques et procédés d'utilisation
WO2025149947A1 (fr) 2024-01-12 2025-07-17 Seagen Inc. Conjugués anticorps-médicament
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
US20250242018A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (fr) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Procédés et compositions pour redosage d'un aav à l'aide d'un anticorps antagoniste anti-cd40 pour supprimer une réponse d'anticorps anti-aav hôte
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1993010260A1 (fr) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Utilisation de la neuraminidase extracellulaire pour lutter contre la degradation d'oligosaccharides de la glycoproteine
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE60045319D1 (de) 1999-02-05 2011-01-13 Samsung Electronics Co Ltd Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern
PL211786B1 (pl) 1999-08-17 2012-06-29 Apoxis Sa Zastosowanie przeciwciała oraz polipeptydu
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CA2465268A1 (fr) 2001-10-24 2003-05-01 National Jewish Medical And Research Center Structures tridimensionnelles de tall-1 et de ses recepteurs parents, proteines modifiees et procedes associes
US20080267965A1 (en) * 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
EP3434275A1 (fr) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Méthode de dépistage de cellules cancéreuses basé sur l'utilisation de conjugués d'auristatin avec anticorps
EP1709072A1 (fr) 2004-01-29 2006-10-11 Genentech, Inc. Variants du domaine extracellulaire de bcma et utilisations de ceux-ci
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
WO2007008848A2 (fr) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Composes de monomethylvaline presentant des modifications carboxy phenylalanine a la terminaison c
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
WO2009052431A2 (fr) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Agents de liaison au cd19 et utilisations de ceux-ci
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
KR101589785B1 (ko) * 2009-03-10 2016-01-28 바이오젠 엠에이 인코포레이티드 항-ｂｃｍａ 항체
US20120201823A1 (en) 2009-10-14 2012-08-09 Schering Corporation April antagonists and methods of use
JP5870400B2 (ja) 2010-04-15 2016-03-01 シアトル ジェネティクス，インコーポレーテッド 標的化ピロロベンゾジアゼピンコンジュゲート
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
EP3786185A1 (fr) 2010-12-06 2021-03-03 Seagen Inc. Anticorps humanises contre liv-1 et leurs utilisations pour traiter le cancer
US20120213768A1 (en) 2011-02-19 2012-08-23 Baylor Research Institute Diagnostic and Therapeutic Uses for B Cell Maturation Antigen
US9409987B2 (en) * 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
SI3415531T1 (sl) * 2011-05-27 2023-12-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) - vezni proteini
KR101412875B1 (ko) 2012-10-04 2014-07-02 삼성전기주식회사 게이트 구동 회로 및 이를 갖는 인버터
ES2937015T3 (es) * 2012-11-01 2023-03-23 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Anticuerpo contra CD269 (BCMA)
JP6061378B2 (ja) * 2012-11-05 2017-01-18 株式会社Ｓｃｒｅｅｎホールディングス 基板処理装置
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
ES2731232T3 (es) 2013-03-15 2019-11-14 Inst Nat Sante Rech Med Método y composición farmacéutica para su uso en el tratamiento y la predicción del infarto de miocardio
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
CA2945620C (fr) 2014-04-14 2022-12-06 Cellectis Recepteurs antigeniques chimeriques specifiques de bcma (cd269), utiles dans l'immunotherapie du cancer
KR102526945B1 (ko) 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
EP2982692A1 (fr) 2014-08-04 2016-02-10 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
EP3209334A2 (fr) 2014-10-20 2017-08-30 Igenica Biotherapeutics, Inc. Nouveaux conjugués anticorps-médicament et composés, compositions et procédés d'utilisation s'y rapportant
HUE054075T2 (hu) 2014-10-29 2021-08-30 Seagen Inc CD40 elleni nem fukozilált antitestek adagolása és bevitele
BR112017010513A2 (pt) 2014-11-20 2018-04-03 F. Hoffmann-La Roche Ag ?cadeias leves comuns e métodos de uso?
EP3023437A1 (fr) 2014-11-20 2016-05-25 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
EP3872094A3 (fr) 2014-12-05 2021-12-08 Memorial Sloan Kettering Cancer Center Anticorps ciblant un antigène de maturation des lymphocytes b et procédés d'utilisation
IL310723A (en) 2015-04-13 2024-04-01 Pfizer Therapeutic antibodies and their uses
CA2985816A1 (fr) 2015-05-15 2016-11-24 The General Hospital Corporation Anticorps antagonistes de la superfamille du recepteur du facteur de necrose anti-tumoral
AU2016302881B2 (en) 2015-08-03 2022-09-15 Bristol-Myers Squibb Company Monoclonal antibodies against BCMA
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017031104A1 (fr) 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations
AU2016353067B2 (en) 2015-11-13 2023-10-05 Sanford Research Anti-BCMA polypeptides and proteins
US20190256608A1 (en) 2015-12-01 2019-08-22 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
SG11201805770UA (en) 2016-02-03 2018-08-30 Amgen Res Munich Gmbh BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
IL311107A (en) 2016-02-17 2024-04-01 Seagen Inc BCMA antibodies and their use for the treatment of cancer and immune disorders
US10689450B2 (en) 2016-04-01 2020-06-23 Kite Pharma, Inc BCMA binding molecules and methods of use thereof
CA3053640A1 (fr) * 2017-02-17 2018-08-23 Unum Therapeutics Inc. Utilisation conjointe d'un anticorps anti-bcma et d'un recepteur de lymphocytes t lie a un anticorps (actr) en cancerotherapie et troubles lies aux lymphocytes b
AU2021244215A1 (en) * 2020-03-26 2022-10-13 Seagen Inc. Methods of treating multiple myeloma

Also Published As

Publication number Publication date
AU2017219747B2 (en) 2023-09-28
US20200002431A1 (en) 2020-01-02
JP2019512464A (ja) 2019-05-16
CN108778329B (zh) 2022-09-16
JP7152309B2 (ja) 2022-10-12
MX2023000889A (es) 2023-10-30
AU2017219747A1 (en) 2018-08-09
US11767365B2 (en) 2023-09-26
US20190194338A1 (en) 2019-06-27
KR102816905B1 (ko) 2025-06-10
CN108778329A (zh) 2018-11-09
CA3011900A1 (fr) 2017-08-24
SG10202007836WA (en) 2020-09-29
JP2024019677A (ja) 2024-02-09
CN116063503A (zh) 2023-05-05
AU2023282281A1 (en) 2024-01-18
HK1259075A1 (zh) 2019-11-22
JP2022069488A (ja) 2022-05-11
IL260732B1 (en) 2024-04-01
SG11201806261XA (en) 2018-09-27
WO2017143069A1 (fr) 2017-08-24
EP3416687A1 (fr) 2018-12-26
IL260732A (en) 2018-10-31
IL260732B2 (en) 2024-08-01
MX2018009700A (es) 2019-01-24
IL311107A (en) 2024-04-01
US20170233484A1 (en) 2017-08-17
NZ744381A (en) 2025-03-28
US20220025062A1 (en) 2022-01-27
BR112018016697A2 (pt) 2018-12-26
EP3416687A4 (fr) 2019-10-23
JP2020073605A (ja) 2020-05-14
KR20180107111A (ko) 2018-10-01
US20240109975A1 (en) 2024-04-04
US20190023801A1 (en) 2019-01-24
US11078291B2 (en) 2021-08-03

Similar Documents

Publication Publication Date Title
EP3416687A4 (fr) Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
EP3265113A4 (fr) Anticorps anti-lilrb et leur utilisation pour détecter et traiter un cancer
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
EP3570844A4 (fr) Azolopyrimidine pour le traitement de troubles liés au cancer
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
EP2931268A4 (fr) Compositions de gamma-hydroxybutyrate et leur utilisation pour le traitement de troubles
EP2968160A4 (fr) Particules de modification immunitaire pour le traitement d'inflammation
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3645040A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de cancers
EP3442567A4 (fr) Anticorps anti-psma et leur utilisation
EP2991631A4 (fr) Nanosupports synthétiques tolérogènes et macromolécules thérapeutiques pour des effets pharmacodynamiques réduits ou améliorés
EP3420002A4 (fr) Antagonistes d'actrii pour leur utilisation dans l'accroissement de l'activité immunitaire
EP3432843A4 (fr) Vêtement de compression pour troubles neurologiques et circulatoires
EP2968470A4 (fr) Protéines de substance d'inhibition mullerienne (mis) modifiées et leurs utilisations pour le traitement de maladies
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l'anxiété et de la dépression
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
EP3383497A4 (fr) Nouveaux anticorps pour le traitement de cancers
EP2970979A4 (fr) Aptamères se liant à l'il-6 et leur utilisation pour traiter ou diagnostiquer les pathologies associées à l'il-6
MA43570A (fr) Thérapie génique pour traiter l'hypercholestérolémie familiale
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
EP2976072A4 (fr) Particules fines d'épinéphrine et méthodes d'utilisation de celles-ci pour le traitement d'états pathologiques réagissant à l'épinéphrine